Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Infection of the retina by cytomegalovirus characterized by retinal necrosis, hemorrhage, vessel sheathing, and retinal edema. Cytomegalovirus retinitis is a major opportunistic infection in aids patients and can cause blindness.
Biomarker and diagnostic research for cytomegalovirus retinitis has been reported in the published literature.
2 FDA-approved treatments are available for cytomegalovirus retinitis, including GANCICLOVIR (GANCICLOVIR, approved 2017) and VALGANCICLOVIR (VALCYTE, approved 2001).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
1 clinical trial registered, 1 recruiting. Interventions under study include drug therapy. Pipeline includes 1 EARLY_PHASE1. Research is primarily sponsored by academic and government institutions.
189 publications have been identified in PubMed for cytomegalovirus retinitis. Kisho has analyzed 115 by research type. Research spans Case Report / Case Series (44%), Epidemiology / Natural History (17%), and Review / Meta-Analysis (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 51 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 7:50 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Genetic and Rare Diseases Info Center
GANCICLOVIR
GANCICLOVIR |
— |
2017 |
Available |
VALCYTE | VALGANCICLOVIR | — | 2001 | Available |
Gene therapy approaches for cytomegalovirus retinitis have been reported in the published literature.
1 trial found
Disease patterns and progression | 19 | 17% |
Research summaries | 17 | 15% |
Testing and diagnosis research | 11 | 10% |
Laboratory research | 8 | 7% |
Other research | 4 | 3% |
New treatment approaches | 3 | 3% |
Clinical study results | 2 | 2% |
Bezci Aygun F (2026). [PMID: 41735812](https://pubmed.ncbi.nlm.nih.gov/41735812/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Wang E (2026). [PMID: 41592257](https://pubmed.ncbi.nlm.nih.gov/41592257/). *Retin Cases Brief Rep*. [Case Report / Case Series]
Tabatabaei SA (2026). [PMID: 41969563](https://pubmed.ncbi.nlm.nih.gov/41969563/). *Ther Adv Ophthalmol*. [Diagnostic / Biomarker]
Wu S (2026). [PMID: 41767320](https://pubmed.ncbi.nlm.nih.gov/41767320/). *Int J Ophthalmol*. [Epidemiology / Natural History]
Pascale R (2026). [PMID: 41553928](https://pubmed.ncbi.nlm.nih.gov/41553928/). *Transpl Infect Dis*. [Other]
Jeong S (2026). [PMID: 41530976](https://pubmed.ncbi.nlm.nih.gov/41530976/). *J Yeungnam Med Sci*. [Review / Meta-Analysis]
Leal I (2026). [PMID: 42119730](https://pubmed.ncbi.nlm.nih.gov/42119730/). *Ophthalmol Retina*. [Diagnostic / Biomarker]
Sidiropoulou M (2026). [PMID: 41702223](https://pubmed.ncbi.nlm.nih.gov/41702223/). *Transplant Rev (Orlando)*. [Review / Meta-Analysis]
Uy H (2026). [PMID: 42172261](https://pubmed.ncbi.nlm.nih.gov/42172261/). *PLOS Glob Public Health*. [Diagnostic / Biomarker]
Amiri I (2026). [PMID: 41986961](https://pubmed.ncbi.nlm.nih.gov/41986961/). *J Int Med Res*. [Case Report / Case Series]
AI-curated news mentioning cytomegalovirus retinitis
Updated Sep 8, 2026
A recent study published in PubMed highlights the reactivation of cytomegalovirus in a patient with colonic tuberculosis, providing insights into the interplay between these infections in immunocompetent individuals. This research may inform future clinical approaches to managing co-infections.
In a recent episode of Denatured, experts discuss the ongoing challenges of cytomegalovirus (CMV) in transplant patients. Ian McGowan from Synklino and James Hunter from Oxford University highlight the need for innovative antiviral strategies to address this persistent issue.
A case report details a pediatric patient with acute lymphoblastic leukemia (ALL) who developed disseminated ganciclovir-resistant cytomegalovirus. This highlights the challenges in managing viral infections in immunocompromised children.